Table 2. The risk of symptomatic UGI events and UGI bleeding in users of nsNSAID+GPA (≥80% adherence) as compared to coxib users.
| Symptomatic UGI events (UGI bleeding and symptomatic ulcer) | UGI bleeding | ||||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Cases | Controls | ORmatch ed (95%CI) |
P- value |
ORadj† (95%CI) |
P- value |
Cases | Controls | ORmatche d (95%CI) |
P-value | ORadj† (95%CI) |
P-value | ||
| n (%) | n (%) | n (%) | n (%) | ||||||||||
|
United
Kingdom |
Coxib | 128 (41.7) |
24,722 (50.6) |
1.00 | 1.00 | 86 (44.3) | 14,835 (51.1) |
1.00 | 1.00 | ||||
| nsNSAID+GPA# | 179 (58.3) |
24,138 (49.4) |
1.02 (0.77- 1.36) |
0.883 | 1.05 (0.77- 1.45) |
0.742 | 108 (55.7) |
14,222 (48.9) |
0.90 (0.63- 1.29) |
0.568 | 1.20 (0.80- 1.80) |
0.375 | |
|
The
Netherlands * |
Coxib | 13 (76.5) | 243 (65.0) | 1.00 | 1.00 | 10 (71.4) | 172 (60.4) | 1.00 | 1.00 | ||||
| nsNSAID+GPA# | 4 (23.5) | 131 (35.0) | 0.44 (0.13- 1.48) |
0.183 | 0.54 (0.16- 1.84) |
0.323 | 4 (28.6) | 113 (39.6) | 0.53 (0.15- 1.88) |
0.326 | 0.63 (0.18- 2.24) |
0.478 | |
| Italy | Coxib | 44 (59.5) | 6,201 (74.4) | 1.00 | 1.00 | 6 (35.3) | 1,124 (64.6) | 1.00 | 1.00 | ||||
| nsNSAID+GPA# | 30 (40.5) | 2,133 (25.6) | 1.22 (0.69- 2.17) |
0.500 | 0.79 (0.27- 2.35) |
0.673 | 11 (64.7) | 616 (35.4) | 2.85 (0.92- 8.80) |
0.069 | 0.59 (0.05- 6.55) |
0.669 | |
|
Pooled on
patient level |
Coxib | 185 (46.5) |
31,166 (54.1) |
1.00 | 1.00 | 102 (45.3) |
16,131 (51.9) |
1.00 | 1.00 | ||||
| nsNSAID+GPA# | 213 (53.5) |
26,402 (45.9) |
1.01 (0.79- 1.30) |
0.918 | 1.02 (0.77- 1.37) |
0.880 | 123 (54.7) |
14,951 (48.1) |
0.96 (0.69- 1.33) |
0.800 | 1.14 (0.78- 1.65) |
0.503 | |
Cases and controls are matched on age, gender and number of individual UGI risk factors.
*
For NL: adjusted model also includes use of antiplatelets.
†
Adjusted for dose of NSAID, length of NSAID episode and density of NSAID use within episode. Only subjects included with known dosage of NSAID (UK 80.2%; NL 100%; IT 35.3%).
#
nsNSAID+GPA (≥80% adherence)